Cantor raises Abeona stock price target on partner drug approval
Cantor Fitzgerald raised its price target on Abeona Therapeutics (NASDAQ:ABEO) to $30 from $28, citing its partner Ultragenyx's drug approval. Abeona is eligible for royalties and milestone payments. Q2 2026 revenue was $11.4M, below estimates, with a net loss of $20.2M. Roth/MKM initiated coverage with a Buy rating and $17 target.
How this was made
The 30-second read
Why it matters
The FDA approval for FAYUVI creates a new revenue stream via royalties and milestones, prompting analyst price‑target increase.
Market read
New regulatory approval and analyst upgrade provide a fresh catalyst for ABEO, suggesting near‑term upside.
What to watch
Potential reimbursement challenges and competition in rare‑disease space.
Background
Abeona Therapeutics (ABEO) is a Nasdaq‑listed biotech focused on rare‑disease gene therapies.
Ticker impact
Cantor raised ABEO price target to $30 after partner Ultragenyx received FDA approval for FAYUVI gene therapy.
Potential upside as market re‑prices royalty upside and milestone expectations.
Analyst upgrade and new regulatory approval are fresh, material catalysts for a micro‑cap biotech.
Market effects
Gene‑therapy sector may see increased investor interest following the approval.
US biotech market gains from new FDA approval.
Highlights progress in rare‑disease treatments, relevant to global biotech investors.
Counterpoint
Royalty upside may be limited if therapy uptake is slower than expected.
Key entities
- CompanyAbeona Therapeutics
Biotech developer of gene therapies.
- CompanyUltragenyx
Partner responsible for development, manufacturing, and commercialization of FAYUVI.
